



(51) International Patent Classification:
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/US2022/023538

(22) International Filing Date:
05 April 2022 (05.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/170,913 05 April 2021 (05.04.2021) US

(71) Applicant: CYTOVIA THERAPEUTICS, LLC.
[US/US]; 18851 NE 29th Avenue, 2nd Floor, Aventura,
Florida 33180 (US).

(72) Inventors: KADOUCHE, Jean; c/o Cytovia Therapeutics,
Inc., 18851 NE 29th Avenue, 2nd Floor, Aventura, Florida
33180 (US). LI, Wei; c/o Cytovia Therapeutics, Inc., 18851
NE 29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).
TEPER, Daniel; c/o Cytovia Therapeutics, Inc., 18851 NE
29th Avenue, 2nd Floor, Aventura, Florida 33180 (US).

(74) Agent: ELRIFI, Ivor et al.; Cooley LLP, 1299 Pennsylva-
nia Ave., NW, Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC ANTIBODIES TARGETING NKP46 AND GPC3 AND METHODS OF USE THEREOF

FIG. 1A





FIG. 1B



(57) **Abstract:** This disclosure provides bispecific antibody molecules that specifically bind to Nkp46 and Glypican 3 (GPC3). The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing Nkp46 and/or GPC3.